

**ASENT2023 Annual Meeting**  
**Virtual Neurotherapeutics Conference**  
**March 13 - 15, 2023**

<b>MONDAY, MARCH 13, 2023</b>			
10:00 a.m. – 10:10 a.m.	Conference Welcome	Welcome & Housekeeping	Jessica Smith, Executive Director, ASENT
10:10 a.m. – 10:20 a.m.	Presidential Intro	Welcome & Introduction	Thomas P. Sutula, MD, PhD, President, ASENT
<b>10:20 a.m. – 12:00 p.m.</b>	<b>Plenary: Presidential Symposium (Unopposed)</b>	<p><b>Co-presented by ASENT-AAN Neurotherapeutics Section - Drug Discovery: The Last Mile in Bringing Drugs to Market</b>            Chair: Sam Frank, MD, Beth Israel Deaconess Medical Center            Co-Chair: Lauren Reoma, MD, NINDS</p> <p>The majority of trial work embarked on by the neurologist and the bulk of industry funded trials are in the phase 2 and phase 3 design space. Often, the development process and resources are focused on earlier stage innovations and design, leading up to the pilot, first-in-human and early phase trials. Beyond initial innovations, building the “last mile” to the pivotal registration trial is key to bringing drugs to market. Important trial methodology structures, innovation in digital designs, and necessary understanding of regulatory safety concerns ensure that early innovation in the drug and device space result in market approvals for our patients.</p>	
11:30 a.m. – 11:45 a.m.	Break		
<b>11:45 a.m. - 1:00 p.m.</b>	<b>Concurrent Symposia</b>	<b>Concurrent Symposium 1</b>	<b>Concurrent Symposium 2</b>
		<p><b>The Brain-Gut connection in Neurodegenerative diseases</b>            Chair: Suhayl Dhib-Jalbut, MD, Rutgers University            Co-Chair: Sharon Tamir, Karyopharm</p> <p>The gut microbiome is believed to play an important role in neurodevelopment, autoimmune, neurodegenerative, and behavioral disorders. Gut dysbiosis, characterized by alterations in intestinal microbial composition and function, is commonly observed in Multiple Sclerosis, Parkinson’s disease, Alzheimer’s disease and ALS. Experimental evidence indicate that gut dysbiosis dysregulates homeostasis of the immune system and its interaction of the latter with the central nervous system. It is believed that diet is one of the most important factors affecting gut microbiota. For example the consumption of a diet high in salt and fat is associated with gut dysbiosis, disruption of intestinal permeability, and production of pro-inflammatory mediators that cause immune dysregulation. On the other hand, diet rich in fiber and short chain fatty acids is thought to promote the growth of beneficial bacteria. This symposium will address the</p>	<p><b>Novel Approaches to Therapy in Epilepsy</b>            Chair: Aditya Joshi, MD, University of Pennsylvania            Co-Chair: Amir Tamiz, PhD, NINDS</p> <p>The treatment of epilepsy remains a vexing problem in spite of an ever-expanding armamentarium of anti-seizure drugs. This symposium will examine some of the work that is being done to accelerate the development of novel treatments for epilepsy.</p>

		influence of the gut microbiome on neurodevelopment, pathogenesis of neurodegenerative disorders, and potential for therapeutic intervention.	
11:45 a.m. – 12:05 p.m.		Presentation 1: Overview of the CNS and the Gut microbiome <b>Sarkis Mazmanian, CalTech</b>	Presentation 1: <b>Ellen Bubrick, MD, FAES, Brigham Health, Brigham and Women's Hospital</b>
12:05 p.m. – 12:25 p.m.		Presentation 2: The Gut Microbiome and MS <b>Sergio E Baranzini, Ph.D., University of California San Francisco</b>	Presentation 2: <b>Karen Wilcox, NINDS Epilepsy Therapy Screening Program</b>
12:25 p.m. – 12:40 p.m.		Presentation 3: Targeting the microbiome with dietary fiber <b>Dr. Liping Zhao, Rutgers University</b>	Presentation 3: <b>Dan Abrams, MD, Cerebral Therapeutics</b>
12:40 p.m. – 1:00 p.m.		Panel Discussion (live)	Panel Discussion (live)
<b>1:00 p.m. – 1:30 p.m.</b>	<b>Sponsored Symposium</b>	TBD	TBD
1:30 p.m. – 1:45 p.m.	Break		
<b>1:45 p.m. – 3:00 p.m.</b>	<b>Journal Symposium</b>	<b>Neurotherapeutics Journal Symposium</b> Chair: Maral Mouradian, MD	
<b>3:00 p.m. - 4:00 p.m.</b>	<b>Posters</b>	<b>Poster Panel Discussion 1</b> Chair: Carolyn Tallon, PhD Live moderated discussion with poster presenters	
<b>4:00 p.m. - 5:00 p.m.</b>	<b>Networking Breakout Rooms</b>	<b>Breakout Rooms</b> Breakout rooms on Drug Discovery, Neurodegenerative Disease, Epilepsy, ALS. Connect live with our speakers and with others who share common interests.	

### TUESDAY, MARCH 14, 2023

<b>TUESDAY, MARCH 14, 2023</b>		
<b>10:00 a.m. – 11:15 a.m.</b>	<b>Plenary (Unopposed)</b>	<p><b>Co-presented by ASENT-JSNT - Neuro-enabled: Next Generation Prosthetics to Restore Function</b> Chair: Kazuo Fujihara, MD, Japanese Society for Neurological Therapeutics Co-Chair: Aditya Joshi, MD, University of Pennsylvania</p> <p>Neurological disorders that impair patients' abilities to interact with the world, can have a devastating impact on their quality of life. Devices that act as interfaces between the brain and an "effector" can go a long way toward helping patients return to a more normal life. In this session, we present three exciting technologies which have the potential to "neuro-enable" patients to restore some of their lost function.</p>

10:00 a.m. – 10:15 a.m.		HAL (hybrid assisted limb) - Yoshihiro Yasunaga, Cyberdyne (Tentative)	
10:15 a.m. – 10:30 a.m.		Hugh Herr, PhD, Massachusetts Institute of Technology Biomechatronics lab	
10:30 a.m. – 10:45 a.m.		Closed loop brain-computer interfaces - Justin Williams, PhD, University of Wisconsin	
10:45 a.m. - 11:00 a.m.		Professor Yukio Nishimura (Neural Prosthetics Project at the Tokyo Metropolitan Institute of Medical Science (Tentative)	
11:00 a.m. – 11:15 a.m.		Panel Discussion (live)	
11:15 a.m. – 11:30 a.m.	Break		
<b>11:30 a.m. – 12:45 p.m.</b>	<b>Concurrent Symposia</b>	<b>Concurrent Symposium 3</b>	<b>Concurrent Symposium 4</b>
		<p><b>Adding Insult to Injury: The Role of Neuroinflammation in Acute Injury to the Nervous System</b>  Chairs: Aditya Joshi, MD, University of Pennsylvania  Co-Chair: Sharon Tamir, Karyopharm</p> <p>There is emerging evidence that neuroinflammation may both mar and mend the nervous system after an acute injury (traumatic brain injury, traumatic spine injury, and acute stroke). In this symposium, we explore some of the newest data on how inflammation may be harnessed to repair the brain and spinal cord, while minimizing additional damage.</p>	<p><b>Bioelectronic devices as therapeutics</b>  Chair: Ludy Shih, MD, MMSc, Boston University Medical Center  Co-Chair: Steve Schachter, MD, Beth Israel Deaconess Medical Center, CIMIT</p> <p>Bioelectronic devices use technologies that record, stimulate, or block neural signaling to affect specific molecular mechanisms. These mechanisms are being studied and developed to treat neurodegenerative diseases, inflammation, and diseases associated with aging. This session will cover programs in preclinical and clinical development as well as regulatory tools and guidance for new medical device developers hoping to bring new therapies to the market.</p>
11:30 a.m. – 11:50 a.m.		Presentation 1: TBI neuroinflammation <b>David J. Loane, Ph.D., Trinity College, University of Dublin</b>	Presentation 1: Kip Ludwig, PhD, University of Wisconsin
11:50 a.m. – 12:10 p.m.		Presentation 2: neuroinflammation after acute stroke Renee Turner, PhD, University of Adelaide, Australia	Presentation 2: Kevin Tracey
12:10 p.m. – 12:30 p.m.		Presentation 3: inflammation in acute spinal cord injury Phillip Popovich, PhD, <b>The Ohio State University</b>	Presentation 3: Introduction to OSEL and Neurological Regulatory Science Tool Development activities <b>Dr. Zane Arp, FDA</b>
12:30 p.m. – 12:45 p.m.		Panel Discussion (live)  *Renee Turner will not participate in live discussion.	Panel Discussion (Live)
12:45 p.m. – 1:00 p.m.	Break		

<b>1:00 p.m. – 3:00 p.m.</b>	<b>Pipeline Presentations (unopposed)</b>	<b>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</b> Chair: C. Anthony Altar, PhD Scientifically relevant pipeline presentations selected following abstract submissions
<b>3:00 p.m. - 4:00 p.m.</b>	<b>Posters</b>	<b>Poster Panel Discussion 2</b> Chair: Carolyn Tallon, PhD Live moderated discussion with poster presenters
<b>4:00 p.m. - 5:00 p.m.</b>	<b>Networking Breakout Rooms</b>	<b>Breakout Rooms</b> Breakout rooms on Neuroinflammation in acute injury, Devices in Neurotherapeutics, Pipeline. Connect live with our speakers and with others who share common interests.

**WEDNESDAY, MARCH 15, 2023**

<b>10:00 a.m. – 11:15 a.m.</b>	<b>Plenary (Unopposed)</b>	<b>Opportunities and Obstacles for Innovators Entering the Field of Neurotherapeutics</b> Chairs: Dietrich Haubenberger and Ludy Shih There are growing opportunities for early career clinician-investigators to contemplate planning a career in the development and testing of novel neurotherapeutics, whether in the academic, government or industry setting. The goal of this session is to introduce trainees and early career faculty to skills needs assessment and training opportunities that may address the specific training needs required for this type of career.	
10:00 a.m. – 10:20 a.m.		<b>Andrew J. Cole, MD, Massachusetts General Hospital</b>	
10:20 a.m. – 10:40 a.m.		<b>Laurie Gutmann, MD, Indiana University School of Medicine</b>	
10:40 a.m. – 11:00 a.m.		<b>Lauren Reoma, MD, NINDS</b>	
11:00 a.m. – 11:15 a.m.		Panel Discussion (live)	
11:15 a.m. – 11:30 a.m.	Break		
<b>11:30 a.m. – 12:45 p.m.</b>	<b>Concurrent Symposia</b>	<b>Concurrent Symposium 5</b>	<b>Concurrent Symposium 6</b>
		<b>Emerging targets and novel approaches in Parkinson's Disease</b> Chair: Debra Ehrlich, MD, NINDS Co-Chair: Amir Tamiz, PhD, NINDS This session will bring perspectives from industry and academia to discuss novel approaches for therapeutics development in Parkinson's disease.	<b>Discovery and Development of Psychedelics for Neuropsychiatric Disorders</b>  Chair: Gail Farfel, PhD Co-Chair: Carolyn Tallon, PhD Neuropsychiatric disorders have been notoriously difficult to develop effective and well tolerated therapeutics. This session will cover the recent advancements in the use of

			psilocybin to treat neuropsychiatric disorders and explore the exciting new doors being opened for developing psychedelics for therapeutic use.
11:30 a.m. – 11:50 a.m.		Presentation 1 Carole Ho, Denali tentative	Presentation 1 TBD
11:50 a.m. – 12:10 p.m.		Presentation 2 David Standaert, UAB	Presentation 2 TBD
12:10 p.m. – 12:30 p.m.		Presentation 3 Malu Tansey, UF	Presentation 3 TBD
12:30 p.m. – 12:45 p.m.		Panel Discussion (live)	Panel Discussion (live)
12:45 p.m. – 1:00 p.m.	Break		
<b>1:00 p.m. – 3:00 p.m.</b>	<b>Pipeline Presentations (unopposed)</b>	<b>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</b> Chair: C. Anthony Altar, PhD Scientifically relevant pipeline presentations selected following abstract submissions	
<b>3:00 p.m. - 4:30 p.m.</b>	<b>Networking Breakout Rooms</b>	<b>Breakout Rooms</b> Breakout rooms on Parkinson's Disease, Psychedelics, Careers in Neurotherapeutics, Pipeline. Connect live with our speakers and with others who share common interests.	